Compare · HNGR vs LH
HNGR vs LH
Side-by-side comparison of Hanger Inc. (HNGR) and Labcorp Holdings Inc. (LH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HNGR and LH operate in Medical Specialities (Health Care), so they compete in similar markets.
- LH carries a market cap of $29.31B.
- LH has hit the wire 13 times in the past 4 weeks while HNGR has been quiet.
- LH has more recent analyst coverage (25 ratings vs 1 for HNGR).
- Company
- Hanger Inc.
- Labcorp Holdings Inc.
- Price
- -
- -
- Market cap
- -
- $29.31B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- 2018
- News (4w)
- 0
- 13
- Recent ratings
- 1
- 25
Hanger Inc.
Hanger, Inc. provides orthotic and prosthetic (O&P) services; and distributes O&P devices and components, manages O&P networks, and provides therapeutic solutions to patients and businesses in acute, post-acute, and clinic settings in the United States. It operates through two segments, Patient Care and Products & Services. The Patient Care segment owns and operates Hanger clinic, which specializes in the design, fabrication, and delivery of custom O&P devices through patient care clinics and satellite locations; and provides payor network contracting services to other O&P providers. The Products & Services segment distributes O&P parts, componentry, and devices to independent O&P providers; and develops specialized rehabilitation technologies and provides evidence-based clinical programs for post-acute rehabilitation to patients at approximately 4,000 skilled nursing and post-acute providers. This segment also manufactures and sells therapeutic footwear for diabetic patients in the podiatric market. As of December 31, 2020, the company operated approximately 704 patient care clinics, and 112 satellite locations in 46 states and the District of Columbia. The company was formerly known as Hanger Orthopedic Group, Inc. and changed its name to Hanger, Inc. in June 2012. Hanger, Inc. was founded in 1861 and is headquartered in Austin, Texas.
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Latest HNGR
- SEC Form SC 13G/A filed by Hanger Inc. (Amendment)
- SEC Form 15-12G filed by Hanger Inc.
- SEC Form EFFECT filed by Hanger Inc.
- SEC Form 4: Sullivan Kathryn M returned $1,162,988 worth of shares to the company (62,026 units at $18.75), closing all direct ownership in the company
- SEC Form 4: Jones Mark M returned $386,138 worth of shares to the company (20,594 units at $18.75), closing all direct ownership in the company
- SEC Form 4: Pettingill Richard returned $1,465,031 worth of shares to the company (78,135 units at $18.75), closing all direct ownership in the company
- SEC Form 4: Ahmad Asif returned $1,328,194 worth of shares to the company (70,837 units at $18.75), closing all direct ownership in the company
- SEC Form 4: Lucchese Cynthia L returned $1,272,206 worth of shares to the company (67,851 units at $18.75), closing all direct ownership in the company
- SEC Form 4: Begley Christopher B returned $1,432,762 worth of shares to the company (76,414 units at $18.75), closing all direct ownership in the company
- SEC Form 4: Hare Stephen E returned $2,006,419 worth of shares to the company (107,009 units at $18.75), closing all direct ownership in the company
Latest LH
- Director Parham Richelle P sold $389,395 worth of shares (1,078 units at $361.22), decreasing direct ownership by 32% to 2,288 units (SEC Form 4)
- EVP, CIO & CTO Oyegunwa Akinbolade converted options into 370 shares and covered exercise/tax liability with 118 shares, increasing direct ownership by 5% to 5,316 units (SEC Form 4) to satisfy tax liability
- EVP and President, Diagnostics Vaughn Bryan T converted options into 500 shares and covered exercise/tax liability with 194 shares, increasing direct ownership by 4% to 7,151 units (SEC Form 4) to cover taxes
- SEC Form 10-Q filed by Labcorp Holdings Inc.
- SEC Form 8-K filed by Labcorp Holdings Inc.
- Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance
- Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026
- Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential
- SEC Form 8-K filed by Labcorp Holdings Inc.
- Labcorp Declares Quarterly Dividend